Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Microcide Pharmaceuticals (NasdaqNM:MCDE)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
July 30Conference call: Microcide Pharmaceuticals Merger Announcement
Location
850 Maude Avenue
Mountain View, CA 94043
Phone: (650) 428-1550
Fax: (650) 428-3550
Email: feubanks@microcide.com
Employees (last reported count): 104
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 24%
·Over the last 6 months:
 · 2 insider buys; 5,000  shares (0.2% of insider shares)
·Institutional: 23% (30% of float)
(25 institutions)
·Net Inst. Selling: 103.0K shares (+4.04%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Microcide Pharmaceuticals Inc. is a biopharmaceutical company committed to the discovery, development and commercialization of novel antimicrobials for the improved treatment of serious bacterial, fungal and viral infections. The Company's three discovery research platforms address the growing problems of antibiotic resistance, and the need for improved antifungal and antiviral therapeutics. The Company's Cephalosporin Antibiotics and Efflux Pump Inhibition platforms focus on developing novel antibiotics and antibiotic potentiators (efflux inhibitors) to directly address existing bacterial and fungal resistance problems. Microcide's Microbial Genomics platform utilizes proprietary bacterial, fungal and viral genetics and genomics tools to discover entirely new classes of antimicrobial agents.
More from Market Guide: Expanded Business Description

Financial Summary
MCDE is a biopharmaceutical co. founded to discover, develop and commercialize novel antibiotics for the treatment of serious bacterial infections. For the three months ended 3/31/01, revenues totaled $2.7 million, up from $1.2 million. Net loss before accounting change decreased 32% to $2.4 million. Revenues reflect an increase in license fees. Net loss was partially offset by increased S/G/A expenses due to higher personnel related costs.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 1,853; after tax earnings were -3,727. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

John Walker, 52
Chairman
--  
George Miller, Ph.D., 62
Sr. VP- R&D
$272K
Donald Huffman, 54
VP of Fin. and Devel., CFO
160K
Jerry Buysse, Ph.D.
VP, Discovery Biology, Assay Devel. and Screening
--  
Michael Dudley
VP, Pharmacology and Microbiology
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:MCDEAs of 31-Aug-2001
Price and Volume
52-Week Low
on 26-Apr-2001
$2.31 
Recent Price$3.96 
52-Week High
on 18-Sep-2000
$15.75 
Beta0.23 
Daily Volume (3-month avg)36.5K
Daily Volume (10-day avg)39.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-57.8%
52-Week Change
relative to S&P500
-43.3%
Share-Related Items
Market Capitalization$45.6M
Shares Outstanding11.5M
Float8.80M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$1.14 
Earnings (ttm)-$1.12 
Earnings (mrq)-$0.32 
Sales (ttm)$0.67 
Cash (mrq*)$1.22 
Valuation Ratios
Price/Book (mrq*)3.47 
Price/EarningsN/A 
Price/Sales (ttm)5.88 
Income Statements
Sales (ttm)$7.72M
EBITDA (ttm*)-$10.8M
Income available to common (ttm)-$12.8M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-50.83%
Return on Equity (ttm)-74.67%
Financial Strength
Current Ratio (mrq*)1.84 
Debt/Equity (mrq*)0.12 
Total Cash (mrq)$11.3M
Short Interest
As of 8-Aug-2001
Shares Short3,000 
Percent of Float0.0%
Shares Short
(Prior Month)
4,000 
Short Ratio0.06 
Daily Volume47.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.